Compile Data Set for Download or QSAR
Report error Found 453 Enz. Inhib. hit(s) with all data for entry = 10266
TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM523906(US11136329, Compound 8 | ethyl 2-(4-((7-(2-ethylbu...)
Affinity DataIC50: 100nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM523907(US11136329, Compound 9 | 2-(4-((7-(2-ethylbutyl)-7...)
Affinity DataIC50: 100nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM523907(US11136329, Compound 9 | 2-(4-((7-(2-ethylbutyl)-7...)
Affinity DataIC50: 100nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM523907(US11136329, Compound 9 | 2-(4-((7-(2-ethylbutyl)-7...)
Affinity DataIC50: 100nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM523907(US11136329, Compound 9 | 2-(4-((7-(2-ethylbutyl)-7...)
Affinity DataIC50: 100nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM523908(US11136329, Compound 10 | ethyl 2-(4-((7-(thiophen...)
Affinity DataIC50: 100nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM523908(US11136329, Compound 10 | ethyl 2-(4-((7-(thiophen...)
Affinity DataIC50: 100nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM523908(US11136329, Compound 10 | ethyl 2-(4-((7-(thiophen...)
Affinity DataIC50: 100nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM523908(US11136329, Compound 10 | ethyl 2-(4-((7-(thiophen...)
Affinity DataIC50: 100nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM523909(US11136329, Compound 11 | 2-(4-((7-(thiophen-3- yl...)
Affinity DataIC50: 100nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM523909(US11136329, Compound 11 | 2-(4-((7-(thiophen-3- yl...)
Affinity DataIC50: 100nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM523909(US11136329, Compound 11 | 2-(4-((7-(thiophen-3- yl...)
Affinity DataIC50: 100nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM523911(US11136329, Compound 13 | ethyl 2-(4-((7- (cyclohe...)
Affinity DataIC50: 100nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM523911(US11136329, Compound 13 | ethyl 2-(4-((7- (cyclohe...)
Affinity DataIC50: 100nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM523906(US11136329, Compound 8 | ethyl 2-(4-((7-(2-ethylbu...)
Affinity DataIC50: 100nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM523906(US11136329, Compound 8 | ethyl 2-(4-((7-(2-ethylbu...)
Affinity DataIC50: 100nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM523906(US11136329, Compound 8 | ethyl 2-(4-((7-(2-ethylbu...)
Affinity DataIC50: 100nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM523918(US11136329, Compound 18 | ethyl 2-(4-((7-(2- cyclo...)
Affinity DataIC50: 100nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM523918(US11136329, Compound 18 | ethyl 2-(4-((7-(2- cyclo...)
Affinity DataIC50: 100nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM523919(US11136329, Compound 19 | 3-(4-((7-(thiophen-3- yl...)
Affinity DataIC50: 100nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM523919(US11136329, Compound 19 | 3-(4-((7-(thiophen-3- yl...)
Affinity DataIC50: 100nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM523919(US11136329, Compound 19 | 3-(4-((7-(thiophen-3- yl...)
Affinity DataIC50: 100nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM523919(US11136329, Compound 19 | 3-(4-((7-(thiophen-3- yl...)
Affinity DataIC50: 100nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM523920(US11136329, Compound 20 | ethyl 2-(4-((7-neopentyl...)
Affinity DataIC50: 100nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM523920(US11136329, Compound 20 | ethyl 2-(4-((7-neopentyl...)
Affinity DataIC50: 100nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM523921(US11136329, Compound 21 | ethyl 2-(4-((7-isopentyl...)
Affinity DataIC50: 100nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM523921(US11136329, Compound 21 | ethyl 2-(4-((7-isopentyl...)
Affinity DataIC50: 100nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM523921(US11136329, Compound 21 | ethyl 2-(4-((7-isopentyl...)
Affinity DataIC50: 100nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM523921(US11136329, Compound 21 | ethyl 2-(4-((7-isopentyl...)
Affinity DataIC50: 100nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM523911(US11136329, Compound 13 | ethyl 2-(4-((7- (cyclohe...)
Affinity DataIC50: 100nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM523911(US11136329, Compound 13 | ethyl 2-(4-((7- (cyclohe...)
Affinity DataIC50: 100nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM523912(US11136329, Compound 14 | ethyl 2-(4-((7- (cyclobu...)
Affinity DataIC50: 100nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM523913(US11136329, Compound 15 | 2-(4-((7- (cyclohexylmet...)
Affinity DataIC50: 100nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM523913(US11136329, Compound 15 | 2-(4-((7- (cyclohexylmet...)
Affinity DataIC50: 100nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM523913(US11136329, Compound 15 | 2-(4-((7- (cyclohexylmet...)
Affinity DataIC50: 100nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM523913(US11136329, Compound 15 | 2-(4-((7- (cyclohexylmet...)
Affinity DataIC50: 100nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM523914(US11136329, Compound 16 | ethyl 3-(4-((7-(thiophen...)
Affinity DataIC50: 100nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM523914(US11136329, Compound 16 | ethyl 3-(4-((7-(thiophen...)
Affinity DataIC50: 100nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM523914(US11136329, Compound 16 | ethyl 3-(4-((7-(thiophen...)
Affinity DataIC50: 100nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM523917(US11136329, Compound 17 | ethyl 2-(4-((7- (cyclope...)
Affinity DataIC50: 100nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM523917(US11136329, Compound 17 | ethyl 2-(4-((7- (cyclope...)
Affinity DataIC50: 100nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM523917(US11136329, Compound 17 | ethyl 2-(4-((7- (cyclope...)
Affinity DataIC50: 100nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM523917(US11136329, Compound 17 | ethyl 2-(4-((7- (cyclope...)
Affinity DataIC50: 100nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM523927(US11136329, Compound 27 | ethyl 2-(4-((7-(2- ethyl...)
Affinity DataIC50: 100nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM523927(US11136329, Compound 27 | ethyl 2-(4-((7-(2- ethyl...)
Affinity DataIC50: 100nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM523927(US11136329, Compound 27 | ethyl 2-(4-((7-(2- ethyl...)
Affinity DataIC50: 100nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetNon-receptor tyrosine-protein kinase TYK2(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM523927(US11136329, Compound 27 | ethyl 2-(4-((7-(2- ethyl...)
Affinity DataIC50: 100nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK1(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM523928(US11136329, Compound 28 | ethyl 2-(4-((7-(2- ethyl...)
Affinity DataIC50: 100nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK2(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM523928(US11136329, Compound 28 | ethyl 2-(4-((7-(2- ethyl...)
Affinity DataIC50: 100nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

TargetTyrosine-protein kinase JAK3(Human)
Vimalan Biosciences

US Patent
LigandPNGBDBM523928(US11136329, Compound 28 | ethyl 2-(4-((7-(2- ethyl...)
Affinity DataIC50: 100nMAssay Description:10 mM test compound stock or 1 mM control compound stock (tofocitinib, ruxolitinib or staurosporine) in DMSO was diluted to 0.4 mM in DMSO. A 3-fold ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
3/27/2022
Entry Details
US Patent

Displayed 1 to 50 (of 453 total ) | Next | Last >>
Jump to: